165 related articles for article (PubMed ID: 15370223)
21. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
[TBL] [Abstract][Full Text] [Related]
22. Donor CD4 T cells convert mixed to full donor T-cell chimerism and replenish the CD52-positive T-cell pool after alemtuzumab-based T-cell-depleted allo-transplantation.
Meyer RG; Wagner EM; Konur A; Bender K; Schmitt T; Hemmerling J; Wehler D; Hartwig UF; Roosnek E; Huber C; Kolbe K; Herr W
Bone Marrow Transplant; 2010 Apr; 45(4):668-74. PubMed ID: 19684624
[TBL] [Abstract][Full Text] [Related]
23. Alemtuzumab in T-cell malignancies.
Dearden CE; Matutes E; Catovsky D
Med Oncol; 2002; 19 Suppl():S27-32. PubMed ID: 12180489
[TBL] [Abstract][Full Text] [Related]
24. CAMPATH-1 antibodies in stem-cell transplantation.
Hale G; Cobbold S; Novitzky N; Bunjes D; Willemze R; Prentice HG; Milligan D; MacKinnon S; Waldmann H;
Cytotherapy; 2001; 3(3):145-64. PubMed ID: 12171722
[TBL] [Abstract][Full Text] [Related]
25. Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen.
Kennedy-Nasser AA; Bollard CM; Myers GD; Leung KS; Gottschalk S; Zhang Y; Liu H; Heslop HE; Brenner MK; Krance RA
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1245-52. PubMed ID: 18940679
[TBL] [Abstract][Full Text] [Related]
26. Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL).
Morris E; Mackinnon S
Transfus Apher Sci; 2005 Feb; 32(1):73-83. PubMed ID: 15737876
[TBL] [Abstract][Full Text] [Related]
27. Prevention of graft vs. host disease with alemtuzumab 'in the bag' decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome.
Novitzky N; Thomas V; du Toit C
Cytotherapy; 2008; 10(1):45-53. PubMed ID: 18202974
[TBL] [Abstract][Full Text] [Related]
28. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
Pawson R; Dyer MJ; Barge R; Matutes E; Thornton PD; Emmett E; Kluin-Nelemans JC; Fibbe WE; Willemze R; Catovsky D
J Clin Oncol; 1997 Jul; 15(7):2667-72. PubMed ID: 9215839
[TBL] [Abstract][Full Text] [Related]
29. Loss of donor chimerism in remission after allogeneic stem cell transplantation of T-prolymphocytic leukemia patients following alemtuzumab induction therapy.
Szuszies CJ; Hasenkamp J; Jung W; Koch R; Trümper L; Wulf GG
Int J Hematol; 2014 Nov; 100(5):425-8. PubMed ID: 25258193
[TBL] [Abstract][Full Text] [Related]
30. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma.
Khorana A; Bunn P; McLaughlin P; Vose J; Stewart C; Czuczman MS
Leuk Lymphoma; 2001 Mar; 41(1-2):77-87. PubMed ID: 11342359
[TBL] [Abstract][Full Text] [Related]
31. Salvage therapy for relapsed mediastinal B-cell lymphoma with allogeneic HLA-identical related donor bone marrow transplantation, donor lymphocyte infusion and IDEC-C2B8.
Ratei R; Matylis A; Krahl D; Arnold R; Stein H; Dörken B; Ludwig WD
Leuk Lymphoma; 2000 Dec; 40(1-2):133-40. PubMed ID: 11426614
[TBL] [Abstract][Full Text] [Related]
32. Effective treatment of a peripheral T-cell lymphoma/lymphoepitheloid cell variant (Lennert's lymphoma) refractory to chemotherapy with the CD-52 antibody alemtuzumab.
Zeitlinger MA; Schmidinger M; Zielinski CC; Chott A; Raderer M
Leuk Lymphoma; 2005 May; 46(5):771-4. PubMed ID: 16019517
[TBL] [Abstract][Full Text] [Related]
33. Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
Chakrabarti S; Hale G; Waldmann H
Transplant Proc; 2004 Jun; 36(5):1225-7. PubMed ID: 15251298
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).
Gautschi O; Blumenthal N; Streit M; Solenthaler M; Hunziker T; Zenhäusern R
Eur J Haematol; 2004 Jan; 72(1):61-3. PubMed ID: 14962265
[TBL] [Abstract][Full Text] [Related]
35. A US Multicenter Collaborative Study on Outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T-Cell Lymphoma.
Moustafa MA; Ramdial JL; Tsalatsanis A; Khimani F; Dholaria B; Bojanini L; Brooks T; Zain J; Bennani NN; Braunstein Z; Brammer JE; Beitinjaneh A; Jagadeesh D; Weng WK; Kumar A; Kharfan-Dabaja MA; Ahmed S; Murthy HS
Transplant Cell Ther; 2024 May; 30(5):516.e1-516.e10. PubMed ID: 38431075
[TBL] [Abstract][Full Text] [Related]
36. Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.
Lockwood CM; Hale G; Waldman H; Jayne DR
Rheumatology (Oxford); 2003 Dec; 42(12):1539-44. PubMed ID: 12949252
[TBL] [Abstract][Full Text] [Related]
37. Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.
Truelove E; Fox C; Robinson S; Pearce R; Perry J; Kirkland K; McQuaker G; Pagliuca A; Johnson P; Russell N; Cook G;
Biol Blood Marrow Transplant; 2015 Mar; 21(3):483-8. PubMed ID: 25490180
[TBL] [Abstract][Full Text] [Related]
38. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H).
Walsh M; Chaudhry A; Jayne D
Ann Rheum Dis; 2008 Sep; 67(9):1322-7. PubMed ID: 18055469
[TBL] [Abstract][Full Text] [Related]
39. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
Mandigers CM; Verdonck LF; Meijerink JP; Dekker AW; Schattenberg AV; Raemaekers JM
Bone Marrow Transplant; 2003 Dec; 32(12):1159-63. PubMed ID: 14647270
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H).
Ru X; Liebman HA
Br J Haematol; 2003 Oct; 123(2):278-81. PubMed ID: 14531909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
